CN105726654A - Anti-viral traditional Chinese medicine composition, premix, concentrate, complex material and application - Google Patents
Anti-viral traditional Chinese medicine composition, premix, concentrate, complex material and application Download PDFInfo
- Publication number
- CN105726654A CN105726654A CN201410760303.3A CN201410760303A CN105726654A CN 105726654 A CN105726654 A CN 105726654A CN 201410760303 A CN201410760303 A CN 201410760303A CN 105726654 A CN105726654 A CN 105726654A
- Authority
- CN
- China
- Prior art keywords
- herba
- medicine
- viral
- present
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 109
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 239000012141 concentrate Substances 0.000 title claims abstract description 11
- 230000000840 anti-viral effect Effects 0.000 title abstract description 9
- 239000011365 complex material Substances 0.000 title abstract 2
- -1 premix Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 24
- 201000010099 disease Diseases 0.000 claims abstract description 23
- 230000003612 virological effect Effects 0.000 claims abstract description 15
- 241000700605 Viruses Species 0.000 claims abstract description 10
- 208000036142 Viral infection Diseases 0.000 claims abstract description 5
- 238000011282 treatment Methods 0.000 claims abstract description 4
- 238000005325 percolation Methods 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 17
- 230000002155 anti-virotic effect Effects 0.000 claims description 16
- 244000144977 poultry Species 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 11
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 239000012567 medical material Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 239000005720 sucrose Substances 0.000 claims description 7
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 3
- 244000144972 livestock Species 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 241000712461 unidentified influenza virus Species 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 16
- 230000009385 viral infection Effects 0.000 abstract description 8
- 241000725681 Swine influenza virus Species 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 5
- 208000015181 infectious disease Diseases 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- 208000010359 Newcastle Disease Diseases 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 241001529821 Agastache Species 0.000 abstract 1
- 241001571736 Lysimachia foenum-graecum Species 0.000 abstract 1
- 244000292697 Polygonum aviculare Species 0.000 abstract 1
- 235000006386 Polygonum aviculare Nutrition 0.000 abstract 1
- 241001673669 Porcine circovirus 2 Species 0.000 abstract 1
- 244000153955 Reynoutria sachalinensis Species 0.000 abstract 1
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 abstract 1
- 241001162994 Rugosus Species 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 74
- 229940079593 drug Drugs 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 241000282898 Sus scrofa Species 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 230000009286 beneficial effect Effects 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N ethyl acetate Substances CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 241000287828 Gallus gallus Species 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 241000282887 Suidae Species 0.000 description 4
- 206010025482 malaise Diseases 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000384 rearing effect Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 239000000273 veterinary drug Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 238000003255 drug test Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 229960000329 ribavirin Drugs 0.000 description 2
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241001062009 Indigofera Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 208000005228 Pericardial Effusion Diseases 0.000 description 1
- 241000202347 Porcine circovirus Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Polymers C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000006334 interstitial nephritis Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Fodder In General (AREA)
Abstract
The present invention discloses an anti-viral traditional Chinese medicine composition, a premix, a concentrate, a complex material and application, the anti-viral traditional Chinese medicine composition comprises active ingredients, and the active ingredients comprise agastache rugosus, giant knotweed, herba eupatorii, lysimachia foenum-graecum and perfoliate knotweed. The anti-viral traditional Chinese medicine composition is mainly used in antiviral infection and prevention and treatment of various viral infection diseases, reduces the incidence of the viral diseases of the animal's body, and improves economic efficiency and the like. The anti-viral traditional Chinese medicine composition has very good control effect on various viral infections such as porcine circovirus type II, swine influenza virus, newcastle diseases virus, has little side and toxic effects, can treat both symptoms and root causes, and is low in cost.
Description
Technical field
The invention belongs to field of traditional Chinese veterinary, relate to a kind of anti virus herb compositions, premix material, concentrate feed and batch and application.
Background technology
Animal viral disease is a big class disease of the more difficult preventing and treating of current aquaculture, due to most of viruses, all to have spread speed fast, Epidemic Scope is wide, can through features such as air bornes, animal tends to colony's morbidity, and morbidity is anxious, and with fervescence, owing to viral infection makes animal body immunity degradation, usually other bacterial infection of secondary, parasitic infection etc..Because virus self variation is fast, utilize vaccine immunity preventive effect undesirable.Modal animal viral disease swine flue, bird flu are popular in the world, and the cost being used for preventing and treating this kind of disease every year is ten hundreds of, carry out destructive injury to especially cultivation industrial belt.Present stage, it is no matter chemicals or Chinese medicine is all a lot of for treating the medicine of viral disease, but owing to being subject to various factors such as drug residue, the impact of the factors such as food safety, chemicals use and developing has significant limitation, the beneficial effect of existing anti virus herb is not as again notable.In order to overcome this situation, finding out effective anti virus herb and just seem very meaningful, the Chinese medicine composition opening up this field just becomes a kind of inexorable trend.
Summary of the invention
The purpose of medicine of the present invention is in that to find out a kind of new anti virus herb composition and method of making the same, and the beneficial effect of said composition antiviral is obvious, and poultry influenza virus, pig circular ring virus П type, newcastle disease virus etc. are all had good prophylactic treatment effect.
Technical problem solved by the invention realizes by the following technical solutions:
The present invention providesOnePlanting anti virus herb compositions, containing active component, described active component is made up of Herba Pogostemonis, Rhizoma Polygoni Cuspidati, Herba Eupatorii, Herba Lysimachiae foenum-graeci, Herba Polygoni cymosi.
Further, counting by weight, described active component is made up of Herba Pogostemonis 40-80 part, Rhizoma Polygoni Cuspidati 30-70 part, Herba Eupatorii 10-30 part, Herba Lysimachiae foenum-graeci 15-30 part, Herba Polygoni cymosi 20-40 part.
Further, counting by weight, described active component is made up of Herba Pogostemonis 50-75 part, Rhizoma Polygoni Cuspidati 45-60 part, Herba Eupatorii 15-26 part, Herba Lysimachiae foenum-graeci 18-28 part, Herba Polygoni cymosi 25-35 part.
Further, counting by weight, described active component is made up of Herba Pogostemonis 60 parts, Rhizoma Polygoni Cuspidati 55 parts, Herba Eupatorii 20 parts, Herba Lysimachiae foenum-graeci 25 parts, Herba Polygoni cymosi 30 parts.
The preparation method that present invention also offers described anti virus herb compositions, it comprises the steps:
1) each medicine material is weighed by weight；
2) being pulverized by each medicine material claimed, by 60-80% ethanol 8-15 times amount as solvent percolation, flow velocity is 5-8mL/min. percolation more than 3 times, merges percolate, the thick paste that concentrate under reduced pressure at low temperature becomes relative density to be 1.3-1.6；
3) the medical material after percolation 40-80 DEG C drying, micronizing；
4) add pharmaceutically acceptable adjuvant, mix with the medicinal residues powder of thick paste and micronizing, prepare into granule.
Wherein, described pharmaceutically acceptable adjuvant includes but not limited to soluble dextrins, soluble starch and/or sucrose.
Wherein, the temperature of concentrate under reduced pressure at low temperature is 55-60 DEG C, and pressure is 0.09-0.1Mpa.
Pharmaceutical composition of the present invention also can add in feedstuff, is used for preparing the somatotrophic feedstuff of fowl, as joined the premix material of routine, in the feedstuff such as concentrate feed and batch.Therefore, the present invention also provides for containing the described premix material of anti virus herb compositions, concentrate feed and batch.
The anti-viral pharmaceutical compositions of the present invention can effectively treat livestock and poultry viral disease, especially poultry influenza virus, pig circular ring virus П type, newcastle disease virus etc. is all had good prophylactic treatment effect.Therefore, the present invention also provides for the application in the medicine of preparation treatment livestock and poultry viral disease of the described anti virus herb compositions.
The authentication method of medicine of the present invention is as follows:
(1) taking this product 2.0g, add methanol 20ml, supersound process 30min, filter, filtrate is evaporated, and adds methanol 5ml and makes dissolving, as need testing solution；Take Rhizoma Polygoni Cuspidati control medicinal material 0.5g, be made in the same way of control medicinal material solution；Take polygonin reference substance again to add methanol and make every 1ml solution containing 0.5mg, as reference substance solution.Test according to thin layer chromatography (" Chinese veterinary pharmacopoeia " 2010 editions 2 annex 32 pages), draw each 1～2 μ 1 of above two solution, put respectively on same silica gel g thin-layer plate (band point sample strip width is l0mm, and striation widths is 8mm), with chloroform one methanol one water (15:5:0.5) for developing solvent, launch, take out, dry, put and inspect under ultra-violet lamp (365nm), in test sample chromatograph, on position corresponding with control medicinal material chromatograph, the speckle of aobvious same color.
(2) this product 2.0g is taken, add petroleum ether (30-60 DEG C) 15ml, supersound process 20min, filter, filtrate volatilizes, residue adds petroleum ether (30-60 DEG C) 1ml makes dissolving, as need testing solution, separately take Herba Eupatorii control medicinal material 1.0g, add petroleum ether (30-60 DEG C) 10ml, it is made in the same way of control medicinal material solution, test according to thin layer chromatography (" Chinese veterinary pharmacopoeia " 2010 editions 2 annex 32 pages), draw each 2 μ of above two solution 1 on same silica gel g thin-layer plate, with petroleum ether (30-60 DEG C)-ethyl acetate (19:1) for developing solvent, launch, take out, dry.Spraying with vanillin-sulfuric acid test solution, it is clear to heat to spot development, inspects under daylight lamp, in test sample chromatograph, on position corresponding with control medicinal material chromatograph, and the speckle of aobvious same color.
(3) take this product 2.0g, add petroleum ether (60-90 DEG C) 50ml, supersound process 30 minutes, considering, and discarded petroleum ether liquid, residue volatilizes solvent, add hot water 25ml, put hot dipping 30min, frequently jolting in 80 DEG C of water-baths, taking out, considered while hot, filtrate adds dilute hydrochloric acid 1, extract 2 times with ethyl acetate jolting, each 30ml, combined ethyl acetate liquid, being evaporated, residue adds methanol 1ml makes dissolving, as need testing solution.Caffeic acid reference substance adds methanol and makes every 1mL solution containing 0.5mg again, as reference substance solution.Test according to thin layer chromatography (" Chinese veterinary pharmacopoeia " 2010 editions 2 annex 32 pages), draw each 2 μ 1 of above two solution, put respectively on same silica gel g thin-layer plate, launch for developing solvent with stone toluene-ethyl acetate-formic acid (5:3:1), open up from 8cm, take out, dry, putting and inspect under uviol lamp (365nm), need testing solution chromatograph, on position corresponding with control medicinal material solution chromatograph, shows the speckle of same color.
Medicine of the present invention is mainly used in antiviral property to be infected, and prevents and treats multiple viral infectious diseases, reduce the sickness rate of animal body viral disease, increase economic efficiency.Medicine of the present invention is to the multiple viral infection such as pig circular ring virus П type, swine influenza virus, newcastle disease virus (NDV) uniformly good prevention effect, and toxic and side effects is little, treating both the principal and secondary aspects of a disease, and medicine is less costly.
The advantage of medicine of the present invention and having the beneficial effects that:
1) effect rapidly, can substantially reduce mortality rate in after medication 24 hours, recover rapidly feed intake, internal length of holding time；
2) improve rapidly the resistance of body, can effectively reduce the secondary infection of other diseases；
3) can detoxify, ease pain, remove oxide, the scavenging activated oxygen infringement to mucosa, stimulate the secretion of cell surface active substance；
4) use safety, have no adverse reaction.
Detailed description of the invention
Following example are used for illustrating the present invention, but are not limited to the scope of the present invention.
Embodiment 1 medicine preparation of the present invention and use
(1) raw material containing following weight parts is weighed:
Herba Pogostemonis 40 parts, Rhizoma Polygoni Cuspidati 30 parts, Herba Eupatorii 10 parts, Herba Lysimachiae foenum-graeci 15 parts, Herba Polygoni cymosi 20 parts.
(2) will each medicine that claim be pulverized by step (1), by 70% ethanol 10 times amount as solvent percolation, flow velocity is 7mL/min, percolation 3 times, merging percolate, low temperature (60 DEG C) concentrating under reduced pressure becomes thick paste (relative density is 1.50) standby, then the medical material after percolation 60 DEG C drying, micronizing is standby, adds the medicinal residues powder preparation that appropriate pharmaceutics adjuvant sucrose obtains with thick paste and micronizing and becomes the 1g granule being equivalent to primary crude drug 1g.
(3) drug use method of the present invention: for multiple constitutional and Secondary cases viral disease, mixed drink: poultry every 1L water adds Chinese medicine 2-4g of the present invention, domestic animal every 1L water adds Chinese medicine 1-2g of the present invention.Mixed feeding: poultry every 1kg feedstuff adds medicine 3-6g of the present invention, domestic animal every 1kg feedstuff adds medicine 2-4g of the present invention, is used in conjunction 5-7 days.
Embodiment 2 medicine preparation of the present invention and use
(1) raw material containing following weight parts is weighed:
Herba Pogostemonis 80 parts, Rhizoma Polygoni Cuspidati 70 parts, Herba Eupatorii 30 parts, Herba Lysimachiae foenum-graeci 30 parts, Herba Polygoni cymosi 40 parts.
(2) each medicine claimed in step (1) is pulverized, by 70% ethanol 10 times amount as solvent percolation, flow velocity is 7mL/min, percolation 3 times, merging percolate, low temperature (60 DEG C) concentrating under reduced pressure becomes thick paste (relative density is 1.50) standby, then the medical material after percolation 60 DEG C drying, micronizing is standby, adds the medicinal residues powder preparation that appropriate pharmaceutics adjuvant sucrose obtains with thick paste and micronizing and becomes the 1g granule being equivalent to primary crude drug 1g.
(3) drug use method of the present invention: for multiple constitutional and Secondary cases viral disease, mixed drink: poultry every 1L water adds Chinese medicine 2-4g of the present invention, domestic animal every 1L water adds Chinese medicine 1-2g of the present invention.Mixed feeding: poultry every 1kg feedstuff adds medicine 3-6g of the present invention, domestic animal every 1kg feedstuff adds medicine 2-4g of the present invention, is used in conjunction 5-7 days.
Embodiment 3 medicine preparation of the present invention and use
(1) raw material containing following weight is weighed:
Herba Pogostemonis 50 parts, Rhizoma Polygoni Cuspidati 45 parts, Herba Eupatorii 15 parts, Herba Lysimachiae foenum-graeci 18 parts, Herba Polygoni cymosi 25 parts.
(2) each medicine claimed in step (1) is pulverized, by 70% ethanol 10 times amount as solvent percolation, flow velocity is 7mL/min, percolation 3 times, merging percolate, low temperature (60 DEG C) concentrating under reduced pressure becomes thick paste (relative density is 1.50) standby, then the medical material after percolation 60 DEG C drying, micronizing is standby, adds the medicinal residues powder preparation that appropriate pharmaceutics adjuvant sucrose obtains with thick paste and micronizing and becomes the 1g granule being equivalent to primary crude drug 1g.
(3) drug use method of the present invention: for multiple constitutional and Secondary cases viral disease, mixed drink: poultry every 1L water adds Chinese medicine 2-4g of the present invention, domestic animal every 1L water adds Chinese medicine 1-2g of the present invention.Mixed feeding: poultry every 1kg feedstuff adds medicine 3-6g of the present invention, domestic animal every 1kg feedstuff adds medicine 2-4g of the present invention, is used in conjunction 5-7 days.
Embodiment 4 medicine preparation of the present invention and use
(1) raw material containing following weight is weighed:
Herba Pogostemonis 75 parts, Rhizoma Polygoni Cuspidati 60 parts, Herba Eupatorii 26 parts, Herba Lysimachiae foenum-graeci 28 parts, Herba Polygoni cymosi 35 parts.
(2) will each medicine that claim be pulverized by step (1), by 70% ethanol 10 times amount as solvent percolation, flow velocity is 7mL/min, percolation 3 times, merging percolate, low temperature (60 DEG C) concentrating under reduced pressure becomes thick paste (relative density is 1.50) standby, then the medical material after percolation 60 DEG C drying, micronizing is standby, adds the medicinal residues powder preparation that appropriate pharmaceutics adjuvant (soluble dextrins, sucrose) obtains with thick paste and micronizing and becomes the 1g granule being equivalent to primary crude drug 1g.
(3) drug use method of the present invention: for multiple constitutional and Secondary cases viral disease, mixed drink: poultry every 1L water adds Chinese medicine 2-4g of the present invention, domestic animal every 1L water adds Chinese medicine 1-2g of the present invention.Mixed feeding: poultry every 1kg feedstuff adds medicine 3-6g of the present invention, domestic animal every 1kg feedstuff adds medicine 2-4g of the present invention, is used in conjunction 5-7 days.
Embodiment 5 medicine preparation of the present invention and use
(1) raw material containing following weight is weighed:
Herba Pogostemonis 60 parts, Rhizoma Polygoni Cuspidati 55 parts, Herba Eupatorii 20 parts, Herba Lysimachiae foenum-graeci 25 parts, Herba Polygoni cymosi 30 parts.
(2) will each medicine that claim be pulverized by step (1), by 70% ethanol 10 times amount as solvent percolation, flow velocity is 7mL/min, percolation 3 times, merge percolate, low temperature (60 DEG C) concentrating under reduced pressure becomes thick paste (relative density is 1.50) standby, again the medical material after percolation 60 DEG C drying, micronizing is standby, adds the medicinal residues powder preparation that appropriate pharmaceutics adjuvant (soluble dextrins, soluble starch, sucrose etc.) obtains with thick paste and micronizing and becomes the 1g granule being equivalent to primary crude drug 1g.
(3) drug use method of the present invention: for multiple constitutional and Secondary cases viral disease, mixed drink: poultry every 1L water adds Chinese medicine 2-4g of the present invention, domestic animal every 1L water adds Chinese medicine 1-2g of the present invention.Mixed feeding: poultry every 1kg feedstuff adds medicine 3-6g of the present invention, domestic animal every 1kg feedstuff adds medicine 2-4g of the present invention, is used in conjunction 5-7 days.
Prevention effect transmissible gastroenteritis of swine is sick for showing medicine of the present invention, carries out clinical observation on the therapeutic effect test to medicine of the present invention, the beneficial effect of of the present invention medicine is expanded on further below by way of test example.
Test example 1
For showing that medicine of the present invention can prevent and treat the beneficial effect of viral disease, this experiment adopts test chicken test, observes the medicine of the present invention beneficial effect to newcastle disease virus.
1 materials and methods
1.1 medicines and reagent
Granule medicament of the present invention, is developed by big north agriculture animal health Technical Research Center, adopts Medications Example 1-embodiment 5 of the present invention to prepare, and ribavirin comparison medicine is purchased from veterinary drug market, Beijing.
1.2 experimental animals, test strain
1.2.1 experimental animal: do not carry out the blue brown chickling in sea of 360 30 ages in days of immunity, is provided by Miyun Region of Beijing's chicken house.
1.2.2 test strain: Newcastle disease strain, be purchased from veterinary drug medicine supervision institute of China.
1.3 test methods
1.3.1 experimental animal packet
Experimental animal is divided into 8 groups, often group 45, respectively test 1 group to testing 8 groups, test 1 group of embodiment 1 medicine to embodiment 5 preparation being respectively adopted medicine of the present invention to the medicine used by test 5 groups, testing 6 groups as drug control group, ribavirin is as control drug, and testing 7 groups is the infection matched group not being administered, testing 8 groups is that blank group does not infect and is not administered, and other rearing conditions are consistent.
1.3.2 test method
Testing 1 group to test 6 groups infected chicken Avian pneumo-encephalitis virus respectively, test 1 group with test 5 groups respectively to the medicine according to the preparation of embodiment 1 to embodiment 5, mix drink, every 1mL water adds medicine 2g of the present invention, freely drinks water, is used in conjunction 7 days；Test 6 groups of drug control groups and add control drug 0.1mg according to every 1mL water, freely drink water, be used in conjunction 7 days；Test 7 groups of infection not to be administered, test 8 groups and do not infect and be not administered, continue after test to observe 15 days.
1.4 observation index
Process of the test is observed the clinical symptoms of each group of chicken, incidence, symptom variation, the death condition etc. of every day.
The analysis of 1.5 data and process
Adopt the PASWStatistics18.0 software significance test to data, the sickness rate of chicken, mortality rate, survival rate etc. are carried out X2 inspection between each group.
1.6 test results and analysis
Result of the test is in Table 1.
The table 1 medicine of the present invention beneficial effect to artificial challenge's newcastle disease virus
| Group | Number of animals (only) | Morbidity number (only) | Sickness rate (%) | Death toll (only) | Mortality rate (%) | Survival number (only) | Survival rate (%) |
| Test 1 group | 45 | 2 | 4.44 | 2 | 4.44 | 43 | 95.56 |
| Test 2 groups | 45 | 1 | 2.22 | 1 | 2.22 | 44 | 97.78 |
| Test 3 groups | 45 | 2 | 4.44 | 2 | 4.44 | 43 | 95.56 |
| Test 4 groups | 45 | 3 | 6.67 | 2 | 4.44 | 43 | 95.56 |
| Test 5 groups | 45 | 0 | 0 | 0 | 0 | 45 | 100 |
| Test 6 groups | 45 | 24 | 53.33 | 22 | 48.89 | 23 | 51.11 |
| Test 7 groups | 45 | 45 | 100 | 44 | 97.78 | 1 | 2.22 |
| Test 8 groups | 45 | 0 | 0 | 0 | 0 | 45 | 100 |
Can see that from table 1 survival rate of drug test group of the present invention and matched group is all high than infecting the survival rate not being administered group, mortality rate and sickness rate are not administered matched group also below infecting, and the beneficial effect of medicine of the present invention is apparently higher than control drug group, and the survival rate of test 5 groups reaches 100%, this is suitable with the normal chicken survival rate not infected, illustrate that drug test group of the present invention is obvious to newcastle disease virus curative effect, and 5 groups of effects of test are best.Result of the test shows that newcastle disease virus is had good prevention effect by medicine of the present invention.
Test example 2
In March, 2014, growing and fattening pigs about the body weight 50kg on Wanzhou prefecture of Chongqing pig farm, part pig sudden onset, appetite is useless absolutely, body temperature raises, dyspnea, and the serious dysentery of some pig is mixed and disorderly by hair, some pig subcutaneous dropsys, there is red pathological changes speckle in skin, and especially extremity are the most obvious.Analysing discovery superficial lymph knot enlargement, pericardial effusion, kidney has interstitial nephritis, top layer to have congestion point, is that pig circular ring virus П type infects after diagnosing.Selecting wherein body weight close, condition of illness is tested by typical 45 pigs, observes the clinical efficacy of medicine of the present invention.By 45 ill pig isolated rearings, being randomly divided into 3 groups, often group 15, testing 1 group is medicine of the present invention, is prepared from by embodiment 5；Mixed drink administration, every 1ml water adds medicine 1g of the present invention, is used in conjunction 5 days；Testing 2 groups is drug control group, with the indigo plant dual anti-medicine of circle as comparison, intramuscular injection, injects by 300kg/10ml, once a day, is used in conjunction 5 days；Test 3 groups as blank group, be not administered.Other rearing conditions are all identical.Result of the test is table 2 such as.
The table 2 medicine of the present invention curative effect table to Porcine Circovirus
| Group | Experimental animal number (head) | Death toll (head) | Mortality rate (%) | Cure number (head) | Cure rate (%) | Total significant figure (head) | Total effective rate (%) |
| Test 1 group | 15 | 0 | 0 | 14 | 93.33 | 15 | 100.00 |
| Test 2 groups | 15 | 3 | 20.00 | 9 | 60.00 | 10 | 66.67 |
| Test 3 groups | 15 | 7 | 46.67 | 3 | 20.00 | 4 | 26.67 |
Result of the test shows, illustrate through overtesting, after the pig medication of medicine group of the present invention, all pigs all take a favorable turn, medicine group of the present invention all has good curative effect with the pig of drug control group compared with blank group, and medicine group of the present invention is evident in efficacy is better than drug control group, show medicine group of the present invention and drug control group significant difference (P < 0.5) through X2 inspection, illustrate that pig circular ring virus П type is infected evident in efficacy by medicine of the present invention.
Test example 3
In December, 2013, piglet 400 is bought on pig farm, Nanchang, about body weight 18-20 kilogram, after raising 7 days, part pig occurs, be increased to 40 DEG C～41.5 DEG C by hair slightly unrest, eyelet pastiness, body temperature, spirit is depressed, crowded together, loss of appetite, rapid breathing, dyspnea, palor or jaundice etc., sometimes shows as the symptoms such as diarrhoea, cough and pigling congenital tremors, is swine influenza virus infection associated diseases through pathologic finding diagnosis.134 ill sick pigs are divided into 7 groups for examination.
Test packet and administration: test is divided into 7 groups, test 1 group and adopt embodiment 1 to prepare, and mixed feeding is administered, and per kilogram feedstuff adds Chinese medicine 3g of the present invention；Testing 2 groups adopts embodiment 2 to prepare, and mixed feeding is administered, and per kilogram feedstuff adds Chinese medicine 3g of the present invention, tests 3 groups and adopts embodiment 3 to prepare, and mixed feeding is administered, and per kilogram feedstuff adds Chinese medicine 3g of the present invention；Testing 4 groups adopts embodiment 4 to prepare, and mixed feeding is administered, and per kilogram feedstuff adds Chinese medicine 3g of the present invention；Testing 5 groups adopts embodiment 5 to prepare, and mixed feeding is administered, and per kilogram feedstuff adds Chinese medicine 3g of the present invention；Testing 6 groups as drug control group, with the Oseltamivir of veterinary drug market purchase as control drug, intramuscular injection, every 300kg/0.1g, blank group is not administered；All the other each group is used in conjunction 5.Continuing after off-test to observe 15, statistical results, in Table 3.
Swine influenza virus infection curative effect of disease is added up by table 3 medicine of the present invention
| Group time | Experimental animal head | Cure head | Dead head | Mortality rate | Cure rate | Effective percentage |
| Test 1 group | 20 | 15 | 1 | 5.00% | 75.00% | 90.00% |
| Test 2 groups | 20 | 16 | 0 | 0.00% | 80.00% | 95.00% |
| Test 3 groups | 20 | 16 | 0 | 0.00% | 80.00% | 95.00% |
| Test 4 groups | 20 | 17 | 0 | 0.00% | 85.00% | 100.00% |
| Test 5 groups | 20 | 18 | 0 | 0.00% | 90.00% | 100.00% |
| Test 6 groups | 20 | 14 | 2 | 10.00% | 70.00% | 85.00% |
| Blank group | 14 | 0 | 5 | 35.71% | 0.00% | 45.67% |
Result of the test shows: compare with blank group, and swine influenza virus infection disease is all had significant curative effect by 6 test group；Compared with drug control group group, swine influenza virus infection diseases prevention and treatment effect to be got well by 5 groups of medicine of the present invention, wherein best to test 5 groups of curative effects.
The above is only the preferred embodiment of the present invention; it should be pointed out that, for those skilled in the art, under the premise without departing from the technology of the present invention principle; can also making some improvements and modifications, these improvements and modifications also should be regarded as protection scope of the present invention.
Claims (10)
1. an anti virus herb compositions, it contains active component, and described active component is made up of Herba Pogostemonis, Rhizoma Polygoni Cuspidati, Herba Eupatorii, Herba Lysimachiae foenum-graeci, Herba Polygoni cymosi.
2. anti virus herb compositions according to claim 1, it is characterised in that count by weight, described active component is made up of Herba Pogostemonis 40-80 part, Rhizoma Polygoni Cuspidati 30-70 part, Herba Eupatorii 10-30 part, Herba Lysimachiae foenum-graeci 15-30 part, Herba Polygoni cymosi 20-40 part.
3. anti virus herb compositions according to claim 2, it is characterised in that count by weight, described active component is made up of Herba Pogostemonis 50-75 part, Rhizoma Polygoni Cuspidati 45-60 part, Herba Eupatorii 15-26 part, Herba Lysimachiae foenum-graeci 18-28 part, Herba Polygoni cymosi 25-35 part.
4. one according to claim 3 is used for anti virus herb compositions, it is characterised in that counting by weight, described active component is made up of Herba Pogostemonis 60 parts, Rhizoma Polygoni Cuspidati 55 parts, Herba Eupatorii 20 parts, Herba Lysimachiae foenum-graeci 25 parts, Herba Polygoni cymosi 30 parts.
5. a preparation method for the anti virus herb compositions described in any one of claim 1-4, it comprises the steps:
1) each medicine material is weighed by weight；
2) being pulverized by each medicine material claimed, by 60-80% ethanol 8-15 times amount as solvent percolation, flow velocity is 5-8mL/min, percolation more than 3 times, merges percolate, the thick paste that concentrate under reduced pressure at low temperature becomes relative density to be 1.3-1.6；
3) the medical material after percolation 40-80 DEG C drying, micronizing；
4) add pharmaceutically acceptable adjuvant, mix with the medicinal residues powder of thick paste and micronizing, prepare into granule.
6. preparation method as claimed in claim 5, it is characterised in that described pharmaceutically acceptable adjuvant includes but not limited to soluble dextrins, soluble starch and/or sucrose.
7. the preparation method as described in claim 5 or 6, it is characterised in that the temperature of concentrate under reduced pressure at low temperature is 55-60 DEG C, pressure is 0.09-0.1Mpa.
8. contain the premix material of anti virus herb compositions described in any one of claim 1-4, concentrate feed and batch.
9. the application in the medicine of preparation treatment livestock and poultry viral disease of the anti virus herb compositions described in any one of claim 1-4.
10. apply as claimed in claim 9, it is characterised in that described virosis includes but not limited to that poultry influenza virus, pig circular ring virus П type and/or newcastle disease virus infect the disease caused.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410760303.3A CN105726654A (en) | 2014-12-12 | 2014-12-12 | Anti-viral traditional Chinese medicine composition, premix, concentrate, complex material and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410760303.3A CN105726654A (en) | 2014-12-12 | 2014-12-12 | Anti-viral traditional Chinese medicine composition, premix, concentrate, complex material and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105726654A true CN105726654A (en) | 2016-07-06 |
Family
ID=56241119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410760303.3A Pending CN105726654A (en) | 2014-12-12 | 2014-12-12 | Anti-viral traditional Chinese medicine composition, premix, concentrate, complex material and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105726654A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101757574A (en) * | 2010-02-08 | 2010-06-30 | 寇忠军 | Oral medication for treating chicken virus disease |
| CN101804162A (en) * | 2010-04-19 | 2010-08-18 | 河南工业大学 | Anti-newcastle disease virus Chinese medicinal composition and preparation method thereof |
| CN103585409A (en) * | 2013-11-18 | 2014-02-19 | 镇江天和生物技术有限公司 | Polygonum cuspidatum and glossy privet fruit mixture and preparation method thereof |
-
2014
- 2014-12-12 CN CN201410760303.3A patent/CN105726654A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101757574A (en) * | 2010-02-08 | 2010-06-30 | 寇忠军 | Oral medication for treating chicken virus disease |
| CN101804162A (en) * | 2010-04-19 | 2010-08-18 | 河南工业大学 | Anti-newcastle disease virus Chinese medicinal composition and preparation method thereof |
| CN103585409A (en) * | 2013-11-18 | 2014-02-19 | 镇江天和生物技术有限公司 | Polygonum cuspidatum and glossy privet fruit mixture and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yasmin et al. | Herbal extracts as antiviral agents | |
| CN101007067A (en) | Antivirus medicine for birds and its preparation method | |
| CN102274314A (en) | Evergreen coccidian powder and preparation method thereof | |
| CN1879814B (en) | Antivirus medicine for birds and method for preparing same | |
| CN1330330C (en) | Antivirus medicinal composition, preparation method and use | |
| CN102657764A (en) | Chinese medicinal powder for preventing and treating chicken coccidiosis and preparation method thereof | |
| CN102872307A (en) | Traditional Chinese medicine oral liquid for preventing and treating virus diseases of poultry and method for preparing traditional Chinese medicine oral liquid | |
| CN104208677B (en) | A kind of anti-newcastle disease, infectious bronchitis, egg-decreasing syndrome, the freeze-dried mixed powder and preparation method thereof of bird flu | |
| CN103860616A (en) | Manyprickle Acathopanax Root extrat, and preparation method and application thereof | |
| CN106389562A (en) | Pudilan Xiaoyan granules, preparation method thereof, and product quality control method | |
| CN103768157A (en) | Veterinary antiviral traditional Chinese medicine Ziqi effervescent granules and preparation method thereof | |
| CN105343229A (en) | Traditional Chinese medicinal composition for preventing and treating colibacillosis of livestock and poultry, and preparation method thereof | |
| CN102813713B (en) | Rhizoma dryopteris crassirhizomae and fructus crataegi composition, preparation method and application of composition | |
| CN105726654A (en) | Anti-viral traditional Chinese medicine composition, premix, concentrate, complex material and application | |
| CN102379920B (en) | Veterinary antiviral and antifebrile drug composition | |
| CN106389717A (en) | Piglet drug-resistant colibacillosis treating traditional Chinese medicine composition | |
| CN108743923A (en) | A kind of compound preparation and preparation method thereof for the antiviral raising immunity of livestock and poultry | |
| CN108186706A (en) | A kind of isatis root-folium isatidis grain for livestock and preparation method thereof | |
| CN105748861B (en) | Anti-stress traditional Chinese medicine composition, preparation method and application thereof | |
| CN103784685B (en) | Chinese medicine composition for the treatment of livestock and poultry virus sexually transmitted disease and its preparation method and application | |
| CN103497933B (en) | One application of strain H9N2 type bird flu strain on vaccine development | |
| CN104524291A (en) | Method for preparing medicine preparation for treating swine fever | |
| CN109223716A (en) | A kind of porcine epidemic diarrhea resisting, swine fever, pseudo- mad dog and tetrad Yolk antibody soluble powder of transmissible gastroenteritis and preparation method thereof | |
| CN109498701A (en) | A kind of Chinese medicine composition and its preparation method and application for preventing and treating goose paramyxovirus | |
| CN102657768A (en) | Chinese medicinal granules for preventing and treating chicken coccidiosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160706 |
|
| RJ01 | Rejection of invention patent application after publication |